Experience
Inmagene Biopharmaceuticals Announces Merger With Ikena Oncology
December 23, 2024
Cooley advised Inmagene Biopharmaceuticals, a privately held, global clinical-stage biotechnology company developing novel therapeutics for immunological and inflammatory diseases, on its definitive merger agreement with Ikena Oncology (Nasdaq: IKNA).
Related contacts
Related Practices & Industries
Tvardi Therapeutics Announces Merger With Cara Therapeutics
December 18, 2024
Cooley advised Tvardi Therapeutics, a privately held, clinical-stage biopharmaceutical company focused on the development of novel, oral, small-molecule therapies targeting STAT3 to treat fibrosis-driven diseases, on its definitive merger agreement to combine in an all-stock transaction with Cara Therapeutics (Nasdaq: CARA), a development-stage biopharmaceutical company that has been leading a new treatment paradigm to improve the lives of patients suffering from pruritus.
Related contacts
Related Practices & Industries
Gracell Biotechnologies Agrees to Acquisition by AstraZeneca for up to $1.2 Billion
December 26, 2023
Cooley advised Gracell Biotechnologies, a global clinical-stage biopharmaceutical company dedicated to developing innovative cell therapies for the treatment of cancer and autoimmune diseases, on its definitive agreement to be acquired by AstraZeneca.
Related contacts
Related Practices & Industries
2023 12 26 Gracell Biotechnologies to be Acquired by AstraZeneca for up to Approximately 1 2 Billion
2023 12 26 Gracell Biotechnologies to be Acquired by AstraZeneca for up to Approximately 1 2 Billion
Related contacts
Related Practices & Industries
Related news and events
Gracell Biotechnologies to be Acquired by AstraZeneca for up to Approximately $1.2 Billion
Admissions and credentials
California